Ortho Clinical Diagnostics
Ortho Clinical Diagnostics, a leading player in the in vitro diagnostics industry, is headquartered in the United States. Founded in 1939, the company has established itself as a pioneer in blood testing and transfusion diagnostics, serving healthcare providers across the globe. With a strong presence in North America, Europe, and Asia, Ortho Clinical Diagnostics focuses on delivering innovative solutions that enhance laboratory efficiency and patient care. The company’s core offerings include advanced blood screening, clinical chemistry, and immunoassay systems, distinguished by their accuracy and reliability. Notable achievements include the development of the first FDA-approved blood screening test for HIV. With a commitment to quality and innovation, Ortho Clinical Diagnostics continues to solidify its market position as a trusted partner in the healthcare sector, driving advancements in diagnostic technology.
DitchCarbon Score
How does Ortho Clinical Diagnostics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ortho Clinical Diagnostics's score of 31 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ortho Clinical Diagnostics's reported carbon emissions
In 2021, Ortho Clinical Diagnostics reported total greenhouse gas emissions of approximately 45,291,000 kg CO2e, comprising 17,320,000 kg CO2e from Scope 1 and 27,971,000 kg CO2e from Scope 2. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 emissions to near zero by 2025. Additionally, Ortho plans to achieve a 30% reduction in Scope 1 and Scope 2 emissions from 2022 levels by 2030. The emissions data is cascaded from its parent company, QuidelOrtho Corporation, reflecting the corporate family's commitment to sustainability. Ortho's initiatives align with industry standards for climate action, demonstrating a proactive approach to mitigating climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | |
|---|---|---|
| Scope 1 | 19,409,000 | 00,000,000 |
| Scope 2 | 26,398,000 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ortho Clinical Diagnostics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
